RxDoctor Payments Data

Tina Hale

Nurse Practitioner · Athens, GANPI 1922355239

Payments from drug & device makers

$6,822in general payments, 2019–2025

Across 249 payments — averaging $27.40 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$735
  • Teleflex LLC$695
  • Bayer$683
  • Astellas Pharma US Inc$589
  • Axonics, Inc.$447
  • Rochester Medical Corporation$424
  • plus $3K from 34 others

What the payments were for

  • Food & beverage$6,50995%
  • Education$3125%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,822 in reported general payments places this provider in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

See all nurse practitioner providers in Georgia

Medicare billing

Part B allowed, 2024
$50,351
Medicare patients
287
Services billed
823

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron68$46,461
GemtesaVibegron45$25,826
Tamsulosin Hcl383$3,735
Testosterone13$3,228
Methenamine Hippurate47$2,988
Estradiol47$2,683
Oxybutynin Chloride ErOxybutynin Chloride168$2,216
Finasteride125$1,566
CefuroximeCefuroxime Axetil61$1,535
Potassium Citrate ErPotassium Citrate11$1,453
Silodosin16$1,434
Alfuzosin Hcl ErAlfuzosin Hcl44$1,006
Testosterone Cypionate37$846
Fesoterodine Fumarate ErFesoterodine Fumarate14$843
Cefdinir39$568

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$589$46,46168 claims
Sumitomo Pharma America, Inc.Gemtesa$279$25,82645 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,328 nurse practitioner providers in Georgia.

Other nurse practitioner in Athens

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →